Suven Life Sciences has secured four product patents.

The company has secured one product patent each from India, Singapore, South Korea and Israel corresponding to the new chemical entities (NCEs), for the treatment of disorders associated with Neurodegenerative diseases. These patents are valid through 2031, 2034, 2034 and 2036 respectively.

Further, the granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents for neurodegenerative disorders, such as for the treatment of cognitive impairment associated with neurodegenerative disorders.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week